PR Newswire·Nov 12, 2026, 8:00 AM ET

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results

LUCD PAVM

Lucid Diagnostics reported EsoGuard is now fully reimbursed by Medicare nationwide, enabling commercial acceleration.
The company received its first Medicare payments in October at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test.
October 2026 set a record for monthly test volume with over 1,800 tests, following 2,871 tests performed in the third quarter.
Total EsoGuard tests performed since launch exceeded 50,000, generating $1.2 million in revenue for the three months ended September 30, 2026.
Lucid held a meeting with CMS leadership regarding the pending MolDX Local Coverage Determination, citing an administrative backlog as the cause for delay.
The Concert EsoGuard coverage policy now includes five health plans, with three additional plans expected to adopt it by year-end.
Two U.S. Department of Veterans Affairs programs launched, with a pipeline of additional VA centers planned.
New billing milestones included a Category III CPT code for EsoCheck and a proposed ICD-10 diagnosis code for positive EsoGuard results.
An 11,991-patient real-world study was published, showing 95% sampling success with no device-related adverse events.
The American Gastroenterological Association draft guidelines named EsoGuard as an alternative to endoscopy with high certainty of evidence.
The company strengthened its balance sheet with a $15.0 million private placement of Series C Convertible Preferred Stock.
As of September 30, 2026, the company held $18.0 million in cash, down from $34.7 million at the end of 2025.
GAAP net loss for the quarter was $6.7 million, or $0.03 per share, while non-GAAP adjusted loss was $10.6 million.
Operating expenses totaled $13.5 million, including $1.5 million in stock-based compensation.
Financial results were filed with the SEC on Form 10-Q on November 12, 2026.

Company: Lucid Diagnostics
Keywords: Lucid Diagnostics